Sagittarius Life Science Corp reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 136.03 million compared to TWD 145.93 million a year ago. Net loss was TWD 10.54 million compared to TWD 23.56 million a year ago. Basic loss per share from continuing operations was TWD 0.32 compared to TWD 0.72 a year ago. Diluted loss per share from continuing operations was TWD 0.32 compared to TWD 0.72 a year ago.
For the nine months, sales was TWD 404.89 million compared to TWD 447.13 million a year ago. Net loss was TWD 55.7 million compared to TWD 64.03 million a year ago. Basic loss per share from continuing operations was TWD 1.71 compared to TWD 1.97 a year ago. Diluted loss per share from continuing operations was TWD 1.71 compared to TWD 1.97 a year ago.